Abstract
In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6 × 106 vs. 5.7 × 106; p < 0.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r = 0.92, p < 0.0001). However, in the qualitative analysis, 5.2% (5/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.
Highlights
In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method
The number of cells obtained using EuroFlow-NGF was significantly higher than that obtained by the DuraClone panel, and the correlation was not so high (r = 0.40; p < 0.0001) (Fig. 4A)
91 (94.8%) and 75 (78.1%) of 96 samples assessed by the EuroFlow-NGF and DuraClone, respectively, > 3 million cells were acquired as recommended by the NCI myeloma working group p anel[18]
Summary
The minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. EuroFlow-NGF, which uses two 8-color tubes, is a highly sensitive (cutoff value, 2 × 1 0−6) and standardized way of detecting M RD11, and the IMWG advocates the use of EuroFlow or equivalent methods to assess MRD. It is more rapid and cost-effective in detecting MRD compared with next-generation s equencing[5,6,9,12,13], the EuroFlow method is too expensive (< 350 USD/sample) to perform under public medical insurances in some countries, including Japan[12,14]. We performed a comparison between the two methods
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
